Guidelines for DOAC use in a high bleeding risk procedure recommend that the patient should

Guidelines for DOAC use in a high bleeding risk procedure recommend that the patient should

• A. Miss or delay morning dose before treatment
• B. Take an extra morning dose
• C. Continue as usual
• D. Stop DOACs indefinitely

Answer: (A)

The main idea is reducing bleeding risk by adjusting DOACs around a high-bleeding-risk procedure. DOACs have relatively short half-lives and predictable action, so pausing them around the time of the procedure lowers the chance of significant bleeding while still protecting the patient outside that window. Missing or delaying the morning dose accomplishes this balance by removing anticoagulant effect during the procedure without stopping treatment for an extended period. Taking an extra morning dose would raise bleeding risk, continuing as usual would not reduce bleeding risk during the procedure, and stopping DOACs indefinitely would leave the patient vulnerable to thromboembolism. After the procedure, DOACs are typically resumed once hemostasis is secured, guided by bleeding and thrombotic risk.

The main idea is reducing bleeding risk by adjusting DOACs around a high-bleeding-risk procedure. DOACs have relatively short half-lives and predictable action, so pausing them around the time of the procedure lowers the chance of significant bleeding while still protecting the patient outside that window. Missing or delaying the morning dose accomplishes this balance by removing anticoagulant effect during the procedure without stopping treatment for an extended period. Taking an extra morning dose would raise bleeding risk, continuing as usual would not reduce bleeding risk during the procedure, and stopping DOACs indefinitely would leave the patient vulnerable to thromboembolism. After the procedure, DOACs are typically resumed once hemostasis is secured, guided by bleeding and thrombotic risk.